Accord Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ACCORD, and what generic alternatives to ACCORD drugs are available?
ACCORD has one hundred and fifty-five approved drugs.
There are four US patents protecting ACCORD drugs. There are three tentative approvals on ACCORD drugs.
There are thirty-five patent family members on ACCORD drugs in eighteen countries and three hundred and eighty-seven supplementary protection certificates in eighteen countries.
Summary for Accord
| International Patents: | 35 |
| US Patents: | 4 |
| Tradenames: | 132 |
| Ingredients: | 129 |
| NDAs: | 155 |
| Patent Litigation for Accord: | See patent lawsuits for Accord |
| PTAB Cases with Accord as petitioner: | See PTAB cases with Accord as petitioner |
Drugs and US Patents for Accord
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accord Hlthcare | SERTRALINE HYDROCHLORIDE | sertraline hydrochloride | TABLET;ORAL | 202825-003 | Nov 7, 2014 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
| Accord Hlthcare | CLOZAPINE | clozapine | TABLET;ORAL | 202873-002 | Nov 25, 2015 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
| Accord Hlthcare | GEMCITABINE HYDROCHLORIDE | gemcitabine hydrochloride | SOLUTION;INTRAVENOUS | 209604-001 | Aug 3, 2017 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | |||||
| Accord Hlthcare | OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE | hydrochlorothiazide; olmesartan medoxomil | TABLET;ORAL | 209281-001 | Feb 7, 2019 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
| Accord Hlthcare | AMITRIPTYLINE HYDROCHLORIDE | amitriptyline hydrochloride | TABLET;ORAL | 202446-002 | Jun 4, 2014 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
| Accord Hlthcare | ROPINIROLE HYDROCHLORIDE | ropinirole hydrochloride | TABLET;ORAL | 204022-001 | Feb 28, 2017 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for ACCORD drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | for Injection | 100 mcg/vial and 500 mcg/vial | ➤ Subscribe | 2015-04-14 |
| ➤ Subscribe | for Injection | 200 mcg/vial | ➤ Subscribe | 2015-05-01 |
International Patents for Accord Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 5242415 | ⤷ Subscribe |
| Japan | 2009523798 | ⤷ Subscribe |
| Canada | 2637569 | ⤷ Subscribe |
| Russian Federation | 2427383 | ⤷ Subscribe |
| Hong Kong | 1126975 | ⤷ Subscribe |
| Mexico | 2020006188 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Accord Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1427415 | C 2011 008 | Romania | ⤷ Subscribe | PRODUCT NAME: APIXABANSI SARURI ACCEPTABILE FARMACEUTIC ALE ACESTUIA; NATIONAL AUTHORISATION NUMBER: RO EU/1/11/691/001, RO EU/1/11/691/002, RO EU/1/11/691/003, RO EU/1/11/691/004, RO EU/1/11/691/005; DATE OF NATIONAL AUTHORISATION: 20110518; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/11/691/001, EU/1/11/691/002, EU/1/11/691/003, EU/1/11/691/004, EU/1/11/691/005; DATE OF FIRST AUTHORISATION IN EEA: 20110518 |
| 0219829 | 06C0029 | France | ⤷ Subscribe | PRODUCT NAME: CLOFARABINE; REGISTRATION NO/DATE IN FRANCE: EU/1/06/334/001 DU 20060529; REGISTRATION NO/DATE AT EEC: EU/1/06/334/001 DU 20060529 |
| 1203761 | 05C0029 | France | ⤷ Subscribe | PRODUCT NAME: CINACALCET; REGISTRATION NO/DATE: EU/01/04/292/001-012 20041022 |
| 0720599 | 122004000026 | Germany | ⤷ Subscribe | PRODUCT NAME: EZETIMIB ODER PHARMAZEUTISCH ANNEHMBARE SALZE DAVON IN KOMBINATION MIT SIMVASTATIN; NAT. REGISTRATION NO/DATE: 58866.00.00 58866.01.00 58866.02.00 58866.03.00 58870.00.00 58870.01.00 58870.02.00 58870.03.00 58874.00.00 58874.01.00 58874.02.00 58874.03.00 58878.00.00 58878.01.00 58878.02.00 58878.03.00 20040402 FIRST REGISTRATION: DE 58866.00.00 - 58866.03.00 58870.00.00 - 58870.03.00 58874.00.00 - 58874.03.00 58878.00.00 - 58878.03.00 20040402 |
| 1427415 | 11C0042 | France | ⤷ Subscribe | PRODUCT NAME: APIXABAN, EVENTUELLEMENT SOUS LA FORME D'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/11/691/001 20110520 |
| 2217577 | 300970 | Netherlands | ⤷ Subscribe | PRODUCT NAME: DUZALLO - ALLOPURINOL/LESINURAD OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/18/1300 20180827 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
